Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
– Ocrevus subcutaneous maintains consistent benefit-risk profile after two years – – New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS – – One-year data reinforce that majority of infants potentially exposed to Ocrevus during pregnancy or breastfeeding exhibit antibody responses – – Fenebrutinib two-year Phase II data demonstrate near-complete … [Read more…]
